Similar articles

• Transient inhibitor to monoclonal antibody-purified factor VIII concentrate.

  Votaw ML, Miller S. Votaw ML, et al. Am J Hematol. 1992 Dec;41(4):297. doi: 10.1002/ajh.2830410417. Am J Hematol. 1992. PMID: 1288295 No abstract available.
• [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].

  Klukowska A, Zieleniewska B. Klukowska A, et al. Acta Haematol Pol. 1994;25(4):349-54. Acta Haematol Pol. 1994. PMID: 7847036 Polish.
• The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.

  Aronson DL. Aronson DL. Transfusion. 1990 Oct;30(8):748-58. doi: 10.1046/j.1537-2995.1990.30891020338.x. Transfusion. 1990. PMID: 2120808 Review. No abstract available.
• [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].

  Weippert M, Anders O, Schmidt M, Roewer J. Weippert M, et al. Beitr Infusionsther. 1990;26:174-8. Beitr Infusionsther. 1990. PMID: 1703823 German.
• Porcine factor VIII therapy in patients with factor VIII inhibitors.

  Hay C, Lozier JN. Hay C, et al. Adv Exp Med Biol. 1995;386:143-51. doi: 10.1007/978-1-4613-0331-2_12. Adv Exp Med Biol. 1995. PMID: 8851022 Review. No abstract available.